Evidence map›Paper›PMID 40495143›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

AREG

Yan Wang, Jiao Li, Yu Zhang, Pingping He, Weiwei Liu, Weirong Zeng, Chaofu Li, Yixuan Gao, Yongchao Zhao, Changyin Shen and 4 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Elevated ST2Arthritis research & therapy · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yan Wang *Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Jiao Li *Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Yu Zhang *Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Pingping He *Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Weiwei LiuDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Weirong ZengDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Chaofu LiDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Yixuan GaoDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Yongchao ZhaoDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Changyin ShenDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Wenming ChenDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Yunhang LiDepartment of Cardiology, Guizhou Provincial Staff Hospital, Guiyang, 550000, China.
Ranzun ZhaoDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
Bei ShiDepartment of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China. shib@zmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancing tissue repair and angiogenesis post-Acute myocardial infarction (AMI) is critical to improving cardiac function and preventing heart failure. Recent studies have highlighted the interaction between immune cells and endothelial cells in post-AMI angiogenesis, yet the specific contributions of different immune cell subsets remain poorly understood. Emerging evidence suggests the presence of a subset of regulatory T cells (Tregs) expressing Amphiregulin (AREG) in infarcted myocardial tissue, with AREG acting as a paracrine protein that plays a key role in angiogenesis. However, whether AREG⁺ Tregs mediate post-AMI angiogenesis and the underlying molecular mechanisms remain unclear. In this study, we demonstrate that Treg activation promotes tissue repair and improves cardiac function after AMI, although it does not significantly impact angiogenesis or endothelial cell behaviors. Notably, overexpression of AREG⁺ Tregs stimulates robust neovascularization post-AMI, reduces myocardial fibrosis, and further enhances cardiac function. Our in vitro data reveal that AREG⁺ Tregs secrete not only AREG but also angiogenic factors such as VEGF and FGF, which promote endothelial cell proliferation, migration, and tube formation. RNA sequencing analysis identifies FoxM1 as a key regulator of this angiogenic process in cardiac microvascular endothelial cells (CMECs). Importantly, inhibition of AREG in Tregs abolishes the FoxM1-dependent angiogenic response.In summary, we identified AREG⁺ Tregs as a distinct cell population driving neovascularization post-AMI, with FoxM1-mediated angiogenesis in CMECs. This may provide a foundation for harnessing specific Treg subsets for cardioprotection following AMI.

Indexed as

AmphiregulinAngiogenesisMyocardial InfarctionMyocardiumNeovascularization, PhysiologicT-Lymphocytes, RegulatoryAnimalsCell MovementCell ProliferationDisease Models, AnimalEndothelial CellsHumansMaleMiceAmphiregulinAreg protein, mouseAcute myocardial infarctionAREGFoxM1NeovascularizationRegulatory T cells

Identifiers

PMID40495143
PMCPMC12153170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.